225 related articles for article (PubMed ID: 38132167)
21. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
[TBL] [Abstract][Full Text] [Related]
22. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
23. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
24. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
[TBL] [Abstract][Full Text] [Related]
25. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
26. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
[TBL] [Abstract][Full Text] [Related]
28. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
[TBL] [Abstract][Full Text] [Related]
29. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
31. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S; Califano R; Reinmuth N; Tamma A; Puri T
Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
33. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y
Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459
[TBL] [Abstract][Full Text] [Related]
34. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.
Song Z; Yu X; Zhang Y
Lung Cancer; 2016 Nov; 101():16-21. PubMed ID: 27794403
[TBL] [Abstract][Full Text] [Related]
36. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
Gu L; Ji W; Xu Y; Han Y; Jian H
Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
38. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
Saiki M; Kitazono S; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Yanagitani N; Horiike A; Ohyanagi F; Oikado K; Ninomiya H; Takeuchi K; Ishikawa Y; Nishio M
Clin Lung Cancer; 2018 Sep; 19(5):435-440.e1. PubMed ID: 29885946
[TBL] [Abstract][Full Text] [Related]
40. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
Wu G; Guo L; Gu Y; Huang T; Liu M; Zou X; Yang B; Huang P; Wen C; Yi L; Liao W; Zhao D; Zhu J; Zhang X; Liu Y; Yin Y; Chen S
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1019-1028. PubMed ID: 35220468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
